Earning Trust Where It Counts: Allurion
Allurion, a medtech disruptor known for its innovative gastric balloon solution, entered 2023 needing to reset. Following a year of reputational challenges across regulators, analysts, customers and internal teams, the business required a strategic communications programme to restore confidence - particularly among clinicians, its most critical audience. Woodrow was brought in to help rebuild trust, reframe the brand and position Allurion for renewed growth in a market where clinical credibility is everything.
Impact
The strategy delivered an 85% increase in positive media coverage within three months and a 283% increase in LinkedIn engagement from core audiences, particularly clinicians. Allurion regained momentum and re-established trust where it mattered most. The campaign left the company with a stronger narrative foundation to support future product, policy and partnership activity and a communications platform capable of sustaining that momentum.
Approach
We built a focused B2B2C communications strategy designed to re-establish credibility and drive clinical engagement. This included creating a new corporate narrative and relaunching Allurion's website with refreshed messaging and clearer audience targeting, developing and running a targeted LinkedIn campaign to engage clinicians around outcomes and credibility, and supporting executive profiling and thought leadership to demonstrate alignment between Allurion's clinical ambition and its internal leadership.
